Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$29.72
$19.73
$9.57
$31.13
$4.11B12.05 million shs3.04 million shs
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
$10.51
$10.51
$3.75
$10.73
$769.27M-0.3219,508 shsN/A
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
$22.19
+0.0%
$21.49
$18.89
$24.32
$2.84B0.98813,098 shs1.07 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$24.81
-3.6%
$31.08
$18.92
$81.73
$2.79B0.734.79 million shs4.04 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+2.87%+6.14%+66.97%+88.82%+41.93%
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.00%0.00%0.00%0.00%0.00%
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
+2.58%-5.81%-0.80%+3.66%-3.75%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-0.50%-2.98%-35.42%-1.30%-57.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$29.72
$19.73
$9.57
$31.13
$4.11B12.05 million shs3.04 million shs
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
$10.51
$10.51
$3.75
$10.73
$769.27M-0.3219,508 shsN/A
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
$22.19
+0.0%
$21.49
$18.89
$24.32
$2.84B0.98813,098 shs1.07 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$24.81
-3.6%
$31.08
$18.92
$81.73
$2.79B0.734.79 million shs4.04 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+2.87%+6.14%+66.97%+88.82%+41.93%
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.00%0.00%0.00%0.00%0.00%
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
+2.58%-5.81%-0.80%+3.66%-3.75%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-0.50%-2.98%-35.42%-1.30%-57.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.00
Buy$43.1445.16% Upside
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.00
N/AN/AN/A
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
3.00
Buy$27.5023.92% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$87.50252.68% Upside

Current Analyst Ratings Breakdown

Latest CNVY, CON, ARWR, and VKTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$80.00
8/19/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$102.00
8/11/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/11/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$60.00
8/8/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$40.00 ➝ $38.00
7/28/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetStrong-Buy$125.00 ➝ $122.00
7/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$31.00 ➝ $38.00
6/25/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$102.00
(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$3.55M1,157.49N/AN/A$1.54 per share19.30
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
$337.60M2.28$0.46 per share22.90$7.35 per share1.43
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
$2.01B1.42$1.90 per share11.71$2.20 per share10.09
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$7.90 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
-$9.98M-$0.10N/A25.63N/A-1.90%0.08%0.05%N/A
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
$166.54M$1.1918.6517.071.987.44%50.84%5.89%10/30/2025 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)

Latest CNVY, CON, ARWR, and VKTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q3 2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million
8/7/2025Q2 2025
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
$0.37$0.37N/A$0.35$537.36 million$550.80 million
7/23/2025Q2 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.44-$0.58-$0.14-$0.58N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
N/AN/AN/AN/AN/A
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
$0.251.13%N/A21.01%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest CNVY, CON, ARWR, and VKTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2025
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
quarterly$0.06251.2%8/21/20258/21/20258/28/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
0.39
4.87
4.87
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.50
2.20
1.60
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
4.75
1.18
1.18
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
25.86
25.86
CompanyEmployeesShares OutstandingFree FloatOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400138.26 million132.31 millionOptionable
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
3,80073.19 million68.66 millionNot Optionable
Concentra Group Holdings Parent, Inc. stock logo
CON
Concentra Group Holdings Parent
11,250128.17 million119.71 millionN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.44 million107.84 millionOptionable

Recent News About These Companies

Where Does VKTX Stock Stand After the Obesity Pill Setback?
5 Stocks Poised to DOUBLE Your Money by 2027

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$29.72 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$29.80 +0.08 (+0.27%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Convey Health Solutions stock logo

Convey Health Solutions NYSE:CNVY

Convey Health Solutions Holdings, Inc. provides technology enabled solutions and advisory services to assist its clients with workflows across product developments, sales, member experience, clinical management, core operations, and business intelligence and analytics. It operates through two segments, Technology Enabled Solutions and Advisory Services. The Technology Enabled Solutions segment offers technology solutions through web-based customizable application that is used to identify, track, and administer contractual services, or benefits provided under a client's plan to its Medicare and Medicaid beneficiaries. It also provides analytics over healthcare data to capture and assess gaps in risk documentation, quality, clinical care, and compliance. The company also offers health plan management, data analytics, supplemental benefit, advisory, and software services. The Advisory Services segment offers sales and marketing strategies, provider network strategies, compliance, star ratings, quality, clinical, pharmacy, analytics, and risk adjustment. It serves government sponsored, medicare advantage, medicare, as well as pharmacy benefits managers. The company was founded in 2001 and is headquartered in Fort Lauderdale, Florida. Convey Health Solutions Holdings, Inc. is a former subsidiary of TPG Cannes Aggregation, L.P.

Concentra Group Holdings Parent stock logo

Concentra Group Holdings Parent NYSE:CON

$22.19 +0.01 (+0.05%)
Closing price 03:59 PM Eastern
Extended Trading
$22.16 -0.03 (-0.14%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company offers occupational and consumer health services, including workers' compensation injury care, urgent care, clinical testing, preventative care, and employer services, as well as wellness programs through occupational health centers and onsite clinics. It also provides Concentra Telemed, a telemedicine solution for the treatment of work-related injuries and illnesses, and employer services; pharmacy solution under the Concentra Pharmacy name; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. The company was founded in 1979 and is based in Mechanicsburg, Pennsylvania. Concentra Group Holdings Parent, Inc. is a subsidiary of Select Medical Corporation.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$24.81 -0.93 (-3.61%)
Closing price 04:00 PM Eastern
Extended Trading
$24.98 +0.18 (+0.71%)
As of 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.